The Evidence for Hypoperfusion as a Factor in Multiple Sclerosis Lesion Development
Open Access
- 4 April 2013
- journal article
- review article
- Published by Hindawi Limited in Multiple Sclerosis International
- Vol. 2013, 1-6
- https://doi.org/10.1155/2013/598093
Abstract
The evidence that hypoxia is a precipitating factor in causing early MS lesions includes increased protein levels of hypoxia-inducible factor-1α; presence of the D-110 hypoxia-inducible protein; increased expression of hypoxia-inducible genes in lesions as well as in adjacent normal-appearing white matter (NAWM); loss of myelin-associated glycoprotein in myelin of early MS lesions; a 50% reduction of blood flow through NAWM with areas of lowest blood flow having the greatest probability of lesion development. Why MS-like lesions develop following hypoxemic insults in some individuals but not in others is likely dependent upon the presence of immune predisposing factors that are governed genetically. Hypoperfusion may be due to decreased arterial supply, restricted venous return, or a combination of these. There are clinical trials ongoing or planned to treat chronic cerebrospinal venous insufficiency (CCSVI) through angioplasty. I suggest that it is important that clinical trials addressing vascular issues in MS should examine how the vascular intervention affects white matter perfusion and determine whether the extent of perfusion recovery and maintenance of this recovery is related to functional recovery and maintenance of functional recovery. Consideration should also be given to the possibility of arterial problems playing a role in hypoperfusion in some MS patients.Keywords
This publication has 50 references indexed in Scilit:
- The updated biology of hypoxia-inducible factorThe EMBO Journal, 2012
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association dataGenome Medicine, 2011
- Are current disease‐modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?Journal of Neurochemistry, 2010
- Disease-modifying therapies in relapsing–remitting multiple sclerosisNeuropsychiatric Disease and Treatment, 2010
- White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosisJournal of the Neurological Sciences, 2009
- Chronic cerebrospinal venous insufficiency in patients with multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Interdependent roles for hypoxia inducible factor and nuclear factor‐κB in hypoxic inflammationThe Journal of Physiology, 2008
- Perfusion Magnetic Resonance Imaging Correlates of Neuropsychological Impairment in Multiple SclerosisJournal of Cerebral Blood Flow & Metabolism, 2007
- Pattern of hemodynamic impairment in multiple sclerosis: Dynamic susceptibility contrast perfusion MR imaging at 3.0 TNeuroImage, 2006